Literature DB >> 11081960

Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research.

C Joffres1, J Graham, K Rockwood.   

Abstract

The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC-Plus), is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. Studies using the CIBIC-Plus have focused on the numeric scores to the exclusion of the textual data. Our study explored both sets of data to evaluate whether the CIBIC-Plus written data supported (a) the clinicians' global evaluation of patients' changes during treatment, and (b) the emergence of consistent treatment effects. The global (numeric) scales of change were inconsistently supported by the textual data provided in the CIBIC-Plus. No consistent treatment effects were noted. Methodological problems presently limit the retrospective use of the CIBIC-Plus textual data. Improved standardization of note-taking in the CIBIC-Plus textual data may allow for a better understanding of the typical profiles and clinical importance of changes seen in the course of dementia treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11081960     DOI: 10.1017/s1041610200006505

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  6 in total

Review 1.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.

Authors:  K Rockwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

3.  Goal setting and attainment in Alzheimer's disease patients treated with donepezil.

Authors:  K Rockwood; J E Graham; S Fay
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

Review 4.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

5.  Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease.

Authors:  Elizabeth Degrush; Mohammed Salman Shazeeb; David Drachman; Zeynep Vardar; Clifford Lindsay; Matthew J Gounis; Nils Henninger
Journal:  Alzheimers Res Ther       Date:  2022-09-17       Impact factor: 8.823

6.  The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.

Authors:  Kenneth Rockwood; Sherri Fay; Mary Gorman; Daniel Carver; Janice E Graham
Journal:  BMC Neurol       Date:  2007-08-30       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.